NEW YORK (GenomeWeb News) – TriLink BioTechnologies announced today a licensing deal with QuantiBact to offer twisted intercalating nucleic acid, or TINA, modified oligos.

TINA molecules are intercalators used to stabilize duplex formation, TriLink said, adding their properties improve the sensitivity and specificity of endpoint and real-time PCR. TriLink will makes TINA-modified oligonucleotides available starting next month.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.